Mirum Pharmaceuticals Inc.

Markets

Commodities

Currencies

Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome

Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD's The Liver Meeting®

Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

loader